Evidence map›Paper›PMID 33991013›Full record

ArticleGlia2021

Elevated fibroblast growth factor-inducible 14 expression transforms proneural-like gliomas into more aggressive and lethal brain cancer.

Nina P Connolly, Rebeca Galisteo, Su Xu, Eli E Bar, Sen Peng, Nhan L Tran, Heather M Ames, Anthony J Kim, Graeme F Woodworth, Jeffrey A Winkles

Open access · greenAbstract read
In one paragraph

Article in Glia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 12 citations in OpenAlex.

  1. Enhanced Glioblastoma Detection ThroughMagnetic resonance in medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nina P ConnollyDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Rebeca GalisteoDepartment of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Su XuDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Eli E BarDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sen PengCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.
Nhan L TranDepartments of Cancer Biology and Neurosurgery, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Heather M AmesMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Anthony J KimDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Graeme F WoodworthDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jeffrey A WinklesDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-3305-1424
University of Maryland, Baltimore · USMayo Clinic in Arizona · USTranslational Genomics Research Institute · US

Funding

Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Quantifying Multiscale Competitive Landscapes of Clonal Diversity in GlioblastomaU01CA220378 · NCI · MAYO CLINIC ARIZONA · PI HU, LELAND, MITCHELL, JOSEPH ROSS · 2017 to 2021
$4.3M
Nanotherapeutic enhancement of interstitial thermal therapy for glioblastomaR01CA269995 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Huang Chiao Huang, Anthony J. Kim · 2023 to 2026
$2.5M
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast CancerR37CA218617 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KIM, ANTHONY J. · 2018 to 2024
$2.4M
Nanotherapeutic treatment of the invasive glioblastoma microenvironmentR01NS107813 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI WOODWORTH, GRAEME F · 2019 to 2023
$2.0M
Targeting Brain Tumor Stem Cells In The Hypoxic MicroenvironmentR01CA187780 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI BAR, ELI E · 2015 to 2019
$1.8M
Microenvironmental Regulation of Alternative Splicing Patterns Drive Aggressive GBM BiologyR21NS106553 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI BAR, ELI E · 2018 to 2020
$432k
NCI NIH HHS R01 CA187780NCI NIH HHS R01 CA269995NCI NIH HHS R37 CA218617NCI NIH HHS T32 CA154274NCI NIH HHS U01 CA220378NINDS NIH HHS R01 NS107813NINDS NIH HHS R21 NS106553
6 · The paper itself

Abstract

High-grade gliomas (HGGs) are aggressive, treatment-resistant, and often fatal human brain cancers. The TNF-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) signaling axis is involved in tissue repair after injury and constitutive signaling has been implicated in the pathogenesis of numerous solid cancers. The Fn14 gene is expressed at low levels in the normal, uninjured brain but is highly expressed in primary isocitrate dehydrogenase wild-type and recurrent HGGs. Fn14 signaling is implicated in numerous aspects of glioma biology including brain invasion and chemotherapy resistance, but whether Fn14 overexpression can directly promote tumor malignancy has not been reported. Here, we used the replication-competent avian sarcoma-leukosis virus/tumor virus A system to examine the impact of Fn14 expression on glioma development and pathobiology. We found that the sole addition of Fn14 to an established oncogenic cocktail previously shown to generate proneural-like gliomas led to the development of highly invasive and lethal brain cancer with striking biological features including extensive pseudopalisading necrosis, constitutive canonical and noncanonical NF-κB pathway signaling, and high plasminogen activator inhibitor-1 (PAI-1) expression. Analyses of HGG patient datasets revealed that high human PAI-1 gene (SERPINE1) expression correlates with shorter patient survival, and that the SERPINE1 and Fn14 (TNFRSF12A) genes are frequently co-expressed in bulk tumor tissues, in tumor subregions, and in malignant cells residing in the tumor microenvironment. These findings provide new insights into the potential importance of Fn14 in human HGG pathobiology and designate both the NF-κB signaling node and PAI-1 as potential targets for therapeutic intervention. MAIN POINTS: This work demonstrates that elevated levels of the TWEAK receptor Fn14 in tumor-initiating, neural progenitor cells leads to the transformation of proneural-like gliomas into more aggressive and lethal tumors that exhibit constitutive NF-κB pathway activation and plasminogen activator inhibitor-1 overexpression.

Indexed as

Brain NeoplasmsGliomaCell Line, TumorFibroblast Growth FactorsHumansNeoplasm InvasivenessReceptors, Tumor Necrosis FactorTumor MicroenvironmentTWEAK ReceptorFibroblast Growth FactorsReceptors, Tumor Necrosis FactorTNFRSF12A protein, humanTWEAK ReceptorFn14glioblastomahigh-grade gliomaNF-κBPAI-1RCAS/tv-a model

Identifiers

PMID33991013
PMCPMC8596752
OpenAlexW3162273639

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.